GlassScriptPhysician profile
Randy C Hancock
NPI 1467432971
$2,492.76
in general payments reported to CMS, 2019-2025
29 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $341 · 2021: $395 · 2022: $698 · 2023: $400 · 2024: $266 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.10 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $444.05 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $135.82 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $134.54 | 2021-2023 | Rexulti |
| Abbvie INC. | $114.97 | 2021-2024 | |
| Novo Nordisk INC | $107.73 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $85.10 | 2023-2024 | Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $76.51 | 2024 | Hetlioz, Fanapt |
| Boston Scientific Corporation | $69.96 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.18 | 2022-2023 | |
| Abiomed | $55.44 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.30 | 2022 | |
| Exact Sciences Corporation | $42.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $41.91 | 2021 | |
| Antares Pharma, INC. | $40.45 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.44 | 2025 | Caplyta |
| Pfizer INC. | $29.65 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $26.12 | 2019 | |
| Acerus Pharmaceuticals Corporation | $25.75 | 2021-2022 | |
| Lucid Diagnostics INC. | $25.74 | 2022 | |
| Dexcom, INC. | $24.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2021 | |
| Strongbridge US INC. | $18.69 | 2020 | |
| Abbott Laboratories | $18.65 | 2023 | Proclaim |
| Tolmar, INC. | $18.18 | 2025 | Jatenzo |
| Pacira Therapeutics, INC. | $17.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.53 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.45 | 2022 | |
| Shire North American Group INC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.